MolecularMD has obtained an exclusive license to LKB1 for diagnostic, prognostic and predictive uses in non-small cell lung cancer patients.
The Dana-Farber Cancer Institute, the Massachusetts General Hospital, the University of North Carolina at Chapel Hill, and The University of Texas Southwestern Medical Center jointly own the patent rights.
MolecularMD scientific affairs liaison Dr. Sabita Sankar said, "MolecularMD's offering of both LKB1 IHC and NGS assays will provide critical additional information to predict responsiveness to both targeted agents and chemotherapy especially in the context of MEK inhibitors in KRAS mutant lung adenocarcinoma."
The company is developing diagnostic assays for LKB1 status such as immunohistochemistry and next generation sequencing tests and provides comprehensive clinical trial support.
Commercialization of companion diagnostic will be supported by providing IVD development and manufacturing capability.
By sublicensing LKB1 technology to clinical reference laboratories and diagnostic assay developers and manufacturers, MolecularMD will support further commercialization.
